Charles River Laboratories Intl. Inc vs Microchip Technology Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $304.01 (market cap $14.23B), while Microchip Technology Inc. trades at $74.37 (market cap $41.01B). The key difference: Microchip Technology Inc. is far larger — about 2.9× Charles River Laboratories Intl. Inc's market cap, and Microchip Technology Inc. pays a 2.41% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | MCHP | |
|---|---|---|
Market Cap | $14.23B | $41.01B |
Volume | 1,176,885 | 9,972,516 |
Sector | Health | Technology |
52-Week High | $310.77 | $102.97 |
52-Week Low | $149.93 | $49.02 |
Typical Hold Time | 33 Days | — |
Enterprise Value | $17.06B | $46.13B |
Dividend Yield | — | 2.41% |
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
Microchip Technology (MCHP) trades at $74.00, down 5.15% over 24 hours amid a bearish technical signal. The company reported a net loss of -$500,000 in 2025, a sharp decline from prior profitability, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion in Ethernet and 48V power portfolios and the completion of the Hailo acquisition, targeting growth in automotive, industrial, and AI-driven data center markets.
Outlook: Strong analyst consensus (69.57% Buy) and a $110.50 price target suggest significant upside potential, driven by AI infrastructure demand and portfolio expansion. Key risks include high valuation multiples, substantial long-term debt of $5.63B, and sensitivity to semiconductor cycle volatility. Earnings recovery in 2026 forecasts is critical for sustaining investor confidence.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →